Clinical Trial Update: Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial in Acute myeloid leukemia reports disease stabilization with a combination of all-trans retinoic acid, valproic acid, and low-dose cytarabine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• All-trans retinoic acid (ATRA) (all-trans retinoic acid)
• Cytarabine (Low-Dose) (cytarabine)
• VALPROIC ACID (Valproic acid)

Snippet

Sponsor: University of Bergen | Conditions: Acute Myelogenous Leukemia | Phase 1, Phase 2 | Status: COMPLETED